In the Phase 3 TEMPO program, AbbVie’s Juvmo elicited significant improvements in motor symptoms and prolonged periods with ...

Michael J. Fox has spent decades navigating Parkinson’s disease while continuing to shape the conversations about the ...

Juvmo (tavapadon) offers a novel, selective D1/D5 dopamine receptor partial agonist mechanism for early monotherapy and adjunctive treatment in Parkinson disease.

FDA gives go-ahead to D1/D5 dopamine agonist tavapadon ...

Target Price (Mid): ~$363Street Target: ~$279Potential Total Return: ~37%Annualized IRR: ~8% / yearWhat Happened?The FDA ...

The actor was diagnosed eight years ago, according to his caretaker.

The FDA approved AbbVie’s once-daily oral drug Juvmo (tavapadon) for adults with Parkinson’s disease. Phase 3 trials found ...

Tavapadon (Juvmo) is the first selective D1/D5 dopamine receptor agonist approved for adult Parkinson disease, positioning a mechanistically differentiated oral, once-daily dopaminergic strategy.

A small study found disease-related odor compounds may show up in skin samples, including from the navel, but much larger trials are needed.

JUVMO™ is the first and only selective D1/D5 receptor agonist approved for adults with Parkinson's disease1 Taken once daily with or without levodopa therapy, JUVMO offers patients ...